Plus Common Stock Total Equity from 2010 to 2024
| PSTV Stock | USD 1.28 0.02 1.59% |
Common Stock Total Equity | First Reported 2001-03-31 | Previous Quarter 12 K | Current Value 15 K | Quarterly Volatility 35 K |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 375.2 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.06, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Common Stock Total Equity |
Latest Plus Therapeutics' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Plus Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Plus Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Plus Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 42,580 | |
| Geometric Mean | 21,868 | |
| Coefficient Of Variation | 122.13 | |
| Mean Deviation | 38,736 | |
| Median | 15,000 | |
| Standard Deviation | 52,003 | |
| Sample Variance | 2.7B | |
| Range | 191K | |
| R-Value | (0.48) | |
| Mean Square Error | 2.2B | |
| R-Squared | 0.23 | |
| Significance | 0.07 | |
| Slope | (5,576) | |
| Total Sum of Squares | 37.9B |
Plus Common Stock Total Equity History
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 8.1 K | 7.6 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.